Bionano Genomics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
BNGO$1.16+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue: | ||
| Product revenue | $27,008,000 | $26,727,000 |
| Service and other revenue | 3,768,000 | 9,389,000 |
| Total revenue | 30,776,000 | 36,116,000 |
| Cost of revenue: | ||
| Cost of product revenue | 28,449,000 | 20,415,000 |
| Cost of service and other revenue | 1,947,000 | 6,135,000 |
| Total cost of revenue | 30,396,000 | 26,550,000 |
| Operating expenses: | ||
| Research and development | 24,803,000 | 54,032,000 |
| Selling, general and administrative | 51,855,000 | 92,758,000 |
| Goodwill impairment | — | 77,280,000 |
| Intangible assets and other long-lived assets impairment | 19,683,000 | — |
| Restructuring costs | 8,022,000 | 741,000 |
| Total operating expenses | 104,363,000 | 224,811,000 |
| Loss from operations | (103,983,000) | (215,245,000) |
| Other income (expense): | ||
| Interest income | 2,101,000 | 3,311,000 |
| Other expense | (10,102,000) | (20,497,000) |
| Total other expense | (8,001,000) | (17,186,000) |
| Loss before income taxes | (111,984,000) | (232,431,000) |
| Provision for income taxes | (33,000) | (62,000) |
| Net loss | $(112,017,000) | $(232,493,000) |
| Net loss per share, basic and diluted | $(88.13) | $(408.60) |
| Weighted-average common shares outstanding, basic and diluted | 1,271,000 | 569,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.